24 July 2025 - Enrollment is on-going in US Phase 1/2a trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, ...
23 July 2025 - SGT-501 has now received FDA fast track, orphan drug and rare paediatric disease designations. ...
21 July 2025 - DualityBio announced that the US FDA has granted fast track designation to its next-generation HER3 targeting antibody ...
21 July 2025 - ProMIS Neurosciences today announced that the US FDA has granted fast track designation to PMN310, the ...
16 July 2025 - The US FDA has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for ...
14 July 2025 - Zenith Epigenetics is pleased to announce the designation of ZEN-3694 as a fast track product by the ...
9 July 2025 - Trethera announced today that the US FDA has granted fast track designation for its novel drug, TRE-515, ...
26 June 2025 - Shanghai Vitalgen announced that its gene therapy drug, VGN-R09b, for the treatment of primary Parkinson’s disease, has ...
30 June 2025 - Minovia Therapeutics announces that the US FDA has granted fast track designation to the Company’s lead investigational ...
27 June 2025 - Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need. ...
10 June 2025 - Duke Street Bio today announced that the US FDA has granted fast track designation to DSB2455, its ...
17 June 2025 - BioAegis Therapeutics announces that the US FDA has granted fast track designation to its lead product candidate, ...
17 June 2025 - Global Phase 2b PRIZM study of zagociguat is currently enrolling participants with MELAS. ...
17 June 2025 - Ferrer has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development ...
16 June 2025 - Solascure today announced that the US FDA has granted fast track designation for its investigational Aurase wound ...